Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia
- 1 January 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (2) , 161-166
- https://doi.org/10.1016/0277-5379(91)90478-v
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in VivoScience, 1990
- Increased drug cytotoxicity at reduced pH counteracts cyclophosphamide resistance in cultured rat mammary carcinoma cellsInternational Journal of Cancer, 1989
- Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effectsCarcinogenesis: Integrative Cancer Research, 1988
- Bivariate flow karyotyping of acute myelocytic leukemia in the BNML rat modelCytometry, 1987
- Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557)Biochemical Pharmacology, 1987
- A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitroCancer Chemotherapy and Pharmacology, 1986
- Development of drug resistance in a murine mammary tumourBritish Journal of Cancer, 1985
- Cross-resistance to alkylating agents in multiple myelomaCancer, 1983
- Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitroBiochemical Pharmacology, 1980
- Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamideBiochemical Pharmacology, 1974